Clinical Trial Update: Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update studying somatostatin to prevent postoperative pancreatic fistula in intermediate-risk patients after pancreaticoduodenectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Fistula

Drugs mentioned

• Somatostatin (somatostatin)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Pancreatic Fistula | Phase 4 | Status: COMPLETED